Immuno-oncological treatment of Non-Small-Cell Lung Cancer (NSCLC) in advanced stage with Nivolumab

被引：0
|
作者：
Venturella, Fabio [1 ]
Cancellieri, Giulia [1 ]
Giammanco, Marco [2 ]
Almerico, Anna Maria [1 ]
Aleo, Igor Daniele
Liga, Anastasia Valentina [1 ]
Mortillaro, Francesca [1 ]
Mistretta, Irene [1 ]
机构：
[1] Univ Palermo, Biol Chem & Pharmaceut Sci & Technol Dept, Palermo, Italy
[2] Univ Palermo, Surg Oncol & Stomatol Disciplines Dept, Palermo, Italy
来源：
JOURNAL OF BIOLOGICAL RESEARCH-BOLLETTINO DELLA SOCIETA ITALIANA DI BIOLOGIA SPERIMENTALE | 2023年 / 96卷 / 01期
关键词：
cancer; lung; immuno-oncology; Nivolumab; SAFETY;
D O I：
10.4081/jbr.2023.11027
中图分类号：
Q [生物科学];
学科分类号：
07 ; 0710 ; 09 ;
摘要：
Immuno-oncology marked a therapeutic revolution in the treatment of cancer. Thanks to the new strategy that aims to awaken the immune system to fight cancer cells, there has been a change in the clinical course in the treatment of advanced Non-Small Cell Lung Cancer ( NSCLC). Our study aimed to evaluate the therapeutic efficacy of nivolumab monotherapy in the treatment of patients with advanced stage IIIB/IV non-small cell lung cancer beyond the second line. The results showed a progression-free survival of 7.35 months and an improvement in the quality of life of patients compared to other treatments. In addition, no type 3 and type 4 adverse reactions were detected in patients treated with Nivolumab. We hope that these results, already promising, will lead to an increase in overall survival in the future.
引用
收藏
页数：4
相关论文
共 50 条
  • [41] Perioperative Nivolumab and Chemotherapy in Non-Small-Cell Lung Cancer
    Verma, Saurav
    Vincent, Mark
    Breadner, Daniel
    NEW ENGLAND JOURNAL OF MEDICINE, 2023, 389 (16): : 1534 - 1534
  • [42] Nivolumab plus ipilimumab in non-small-cell lung cancer
    Reck, Martin
    Borghaei, Hossein
    O'Byrne, Kenneth J.
    FUTURE ONCOLOGY, 2019, 15 (19) : 2287 - 2302
  • [43] Nivolumab in non-small-cell lung cancer with EGFR mutation
    Yoshida, H.
    Kim, Y. H.
    Ozasa, H.
    Nagai, H.
    Sakamori, Y.
    Tsuji, T.
    Nomizo, T.
    Yasuda, Y.
    Funazo, T.
    Hirai, T.
    ANNALS OF ONCOLOGY, 2018, 29 (03) : 777 - 778
  • [44] The safety of nivolumab for the treatment of advanced non-small cell lung cancer
    Metro, Giulio
    Ricciuti, Biagio
    Brambilla, Marta
    Baglivo, Sara
    Soli, Irene
    Minenza, Elisa
    Leonardi, Giulia Costanza
    D'arpino, Alessandro
    Colabrese, Daniela
    Tazza, Marco
    Zicari, Daniela
    Minotti, Vincenzo
    Chiari, Rita
    EXPERT OPINION ON DRUG SAFETY, 2017, 16 (01) : 101 - 109
  • [45] Emerging role of gefitinib in the treatment of non-small-cell lung cancer (NSCLC)
    Tiseo, M.
    Bartolotti, M.
    Gelsomino, F.
    Bordi, P.
    DRUG DESIGN DEVELOPMENT AND THERAPY, 2010, 4 : 81 - 98
  • [46] Review of economic analyses of treatment for non-small-cell lung cancer (NSCLC)
    Vergnenegre, Alain
    Chouaid, Christos
    EXPERT REVIEW OF PHARMACOECONOMICS & OUTCOMES RESEARCH, 2018, 18 (05) : 519 - 528
  • [47] Nivolumab for squamous-cell non-small-cell lung cancer
    Yaqub, Farhat
    LANCET ONCOLOGY, 2015, 16 (07): : E319 - E319
  • [48] Surgery for Elderly Patients with Stage III Non-Small-Cell Lung Cancer (NSCLC)?
    Passlick, B.
    JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (10) : S91 - S92
  • [49] CONTINUATION MAINTENANCE FOR ELDERLY PATIENTS WITH ADVANCED NON-SMALL-CELL LUNG CANCER (NSCLC)
    Okamoto, Isamu
    ANNALS OF ONCOLOGY, 2014, 25
  • [50] INDIVIDUALIZED CHEMOTHERAPY (CT) IN PATIENTS WITH ADVANCED NON-SMALL-CELL LUNG CANCER (NSCLC)
    Obodnikov, Oleksandr O.
    Orlovsriy, Oleksiy A.
    Parshikov, Oleksandr V.
    JOURNAL OF THORACIC ONCOLOGY, 2011, 6 (06) : S1280 - S1281
12345